quality-adjusted life year
Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?
... In a resource-constrained society, economic evaluations – particularly cost–utility analyses (CUA) – are increasingly used as important tools to support efficient health resource allocation. For the CUA to become a ...
8
Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia
... threshold should represent the value a society attaches to a QALY, individual valuations of personal health gains can be directly elicited using contingent valuation (CV). In the recently performed European Value of a ...
9
Headroom beyond the quality adjusted life year
... Headroom analysis in early evaluation of diagnostic technologies not expected to result in QALY gain: The case of complex paediatric neurology K.J.M.. van Nimwegen1, R.J.[r] ...
11
Willingness to pay for one quality-adjusted life year in Iran
... improve quality of life, a cross-sectional household survey and face-to-face interviews were con- ducted with a representative general population of 1002 in Tehran, Iran from April to June ...
10
Is an ounce of prevention worth a pound of cure? : Estimates of the impact of English public health grant on mortality and morbidity
... Recent studies of the marginal productivity of National Health Service (NHS) expenditure in England suggest a cost per quality-adjusted life year (QALY) of between £5,000 and £15,000 (Claxton ...
36
Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study
... Background: The aim of this study was to compare the efficacy, safety, costs, and cost-effectiveness of biphasic insulin aspart 30 (BIAsp 30) with NPH plus regular human insulin (NPH/Reg) in patients with type 2 diabetes ...
9
A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal
... reduced quality of life, being comparable to that of major depressive disorder and to chronic illnesses such as diabetes and arthritis, and high consumption of health care ...0.738 quality ...
8
Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case
... per quality adjusted life year (QALY) and incremental cost per vision year gained) of PDT for two cohorts of patients (one with starting visual acuity (VA) of 20/40 and one at 20/100) ...
7
METFORMIN THE TIME TESTED TRUSTWORTHY MEDICINE IN THE MANAGEMENT OF TYPE 2 DIABETES
... and quality of life revealed that the drug was cost saving and that it increased life ...for quality adjusted life year gained, intensive blood glucose control with ...
18
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis
... per quality adjusted life year gained by using any of the four treatments ranged from £42 000 ($66 469; € 61 630) to £98 000 based on efficacy information in the public ...
7
Cost effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU acquired candidemia among patients with sepsis: a model simulation
... withhold treatment until culture confirmation. We conducted an analysis in a hypothetical cohort of 1000 patients in the ICU. We marched this cohort through each branch of the deci- sion tree separately to either death ...
11
An economic evaluation of an augmented cognitive behavioural intervention vs. computerized cognitive training for post-stroke depressive symptoms
... Health-related quality of life; CBT: Cognitive behavioural therapy; HADS: Hospital anxiety and depression subscale; QALY: Quality-adjusted life year; EQ-5D-3 L: Three-level ...
12
Clinical effectiveness and cost effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation
... Statistics life table for English men aged 45 to 65 ...subsequent year thereafter was the same as that for the SC survivors to that ...each year of PEG ...£105K/quality adjusted ...
16
Cost-effectiveness of ablation of ventricular tachycardia in ischaemic cardiomyopathy: limitations in the trial evidence base
... per quality- adjusted life- year gained, over a 5- year time ...frequent quality of life assessments are needed to provide more robust and informed cost- effectiveness ...
8
MRI-guided pulmonary vein isolation for atrial fibrillation: what is good enough? An early health technology assessment
... Cost- effectiveness has become a central question for new innovations due to rapidly increasing healthcare costs. Cost effects of new innovations (such as iMRI- EAM guided PVI therapy) should be balanced with clinical ...
7
Cost Utility Analysis of Radiographic Screening for an Orbital Foreign Body before MR Imaging
... per quality-adjusted life-year (QALY) of ...a life expectancy of 30 years, and if the value of a dollar today is identical to the value of a dollar 30 years hence, then we must be ...
8
Update: Eliciting societal preferences for weighting QALY's according to burden of illness, size of gain and end of life
... Economic evaluation is used to inform decisions related to setting priorities in health care and whether health care interventions should be reimbursed. A widely used method is to enumerate the cost-effectiveness of an ...
38
Where’s WALY? : A proof of concept study of the ‘wellbeing adjusted life year’ using secondary analysis of cross sectional survey data
... of life and the quality of that ...of Quality-Adjusted Life Years ...in quality of life between people with different stages of disease severity, and a limited ability to ...
10
Disability-Adjusted Life-Year Burden of Abusive Head Trauma at Ages 0–4
... and pediatricians to use in assessing infants and children with AHT. Based on pilot testing, we supplemented the HUI-2 responses by adding a “ child is too young to judge ” response category for ambulation and cognitive ...
8
Cost-effectiveness of pulse-echo ultrasonometry in osteoporosis management
... Discounted quality-adjusted life-years (QALYs), payer costs (year 2016 value) at per patient and population level, and cost-effectiveness accept- ability frontiers were modeled as secondary ...
14